Samir K Gupta
Overview
Explore the profile of Samir K Gupta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1849
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
The steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis
Gupta S, Friedman A, Desta Z
AIDS
. 2025 Jan;
39(4):356-361.
PMID: 39761595
Objective: Fixed dose combination (FDC) dolutegravir (DTG) plus rilpivirine (RPV) is an approved antiretroviral treatment regimen for people with HIV. The steady-state pharmacokinetics of FDC DTG+RPV in hemodialysis has not...
2.
Lin K, Vilar-Gomez E, Corey K, Connelly M, Gupta S, Lake J, et al.
Lipids Health Dis
. 2024 Oct;
23(1):339.
PMID: 39420356
Background: Metabolic dysfunction associated steatotic liver disease (MASLD) is associated with increased cardiovascular disease (CVD) risk in persons with HIV (PWH). The lipidomic and metabolomic alterations contributing to this risk...
3.
Fitch K, Zanni M, Manne-Goehler J, Diggs M, Gattu A, Currier J, et al.
Ann Intern Med
. 2024 Oct;
177(11):1449-1461.
PMID: 39374532
Background: REPRIEVE (Randomized Trial to Prevent Vascular Events in HIV) led to new guidelines for statin use among people with HIV (PWH) with low to moderate risk for atherosclerotic cardiovascular...
4.
Schuiling M, Shell A, Callahan C, Nurnberger Jr J, MacDonald K, Considine R, et al.
Psychol Med
. 2024 Sep;
:1-14.
PMID: 39252547
Background: Depression is an independent risk factor for cardiovascular disease (CVD), but it is unknown if successful depression treatment reduces CVD risk. Methods: Using eIMPACT trial data, we examined the...
5.
Crawford C, Polanka B, Wu W, MacDonald K, Gupta S, Stewart J
J Health Psychol
. 2024 Aug;
30(3):590-596.
PMID: 39148313
We assess associations of somatic and cognitive/affective depressive symptom clusters with monocyte activation (soluble (s)CD14, sCD163), systemic inflammation (interleukin-6 (IL-6), high-sensitivity C-reactive protein (hsCRP)), and coagulation (D-dimer, fibrinogen) in people...
6.
Pryke L, Liu Z, Khaitan A, Sims E, Gupta S
AIDS
. 2024 Aug;
38(11):1725-1727.
PMID: 39088830
We explored the impact of immune dysregulation on pancreatic beta cell injury in HIV patients. Analyzing 105 participant samples, we observed lower IL-21 levels and elevated immune checkpoint levels (e.g....
7.
Fusco D, Malenica I, Gunthard H, Gupta S, Kurbegov D, Balani B, et al.
Clin Infect Dis
. 2024 Jun;
79(5):1182-1189.
PMID: 38920297
Background: Remdesivir, an RNA-polymerase prodrug inhibitor approved for treatment of coronavirus disease 2019 (COVID-19), shortens recovery time and improves clinical outcomes. This prespecified analysis compared remdesivir plus standard of care...
8.
Bourgi K, Ofner S, Musick B, Wools-Kaloustian K, Humphrey J, Diero L, et al.
Open Forum Infect Dis
. 2023 Dec;
10(12):ofad581.
PMID: 38088979
Background: Switching from non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens to dolutegravir (DTG) has been associated with greater weight gain. Methods: We conducted our analysis using a longitudinal cohort of people...
9.
Eadon M, Rosenman M, Zhang P, Fulton C, Callaghan J, Holmes A, et al.
Pharmacogenomics J
. 2023 Sep;
23(6):169-177.
PMID: 37689822
Adverse drug events (ADEs) account for a significant mortality, morbidity, and cost burden. Pharmacogenetic testing has the potential to reduce ADEs and inefficacy. The objective of this INGENIOUS trial (NCT02297126)...
10.
Stack M, Hiles J, Valinetz E, Gupta S, Butt S, Schneider J
Open Forum Infect Dis
. 2023 Aug;
10(8):ofad420.
PMID: 37636518
Background: Cryptococcal meningitis is an uncommon but serious infection with high mortality and morbidity. Classically described in immunocompromised patients, including those with solid organ transplants or HIV/AIDS, cryptococcosis has also...